These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23698748)

  • 1. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
    Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
    J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
    Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
    J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
    Zhu L; Zhao L; Wu M; Chen Z; Li H
    Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
    Garrett JT; Rawale S; Allen SD; Phillips G; Forni G; Morris JC; Kaumaya PT
    J Immunol; 2007 Jun; 178(11):7120-31. PubMed ID: 17513761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
    Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
    J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Approach in Designing a Novel Multi-Epitope Vaccine Candidate against Non-Small Cell Lung Cancer with Overexpressed G Protein-Coupled Receptor 56.
    Herrera LRM
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2297-2306. PubMed ID: 32856858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
    Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
    Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with synthetic VEGF peptides in ovarian cancer.
    Wang B; Kaumaya PT; Cohn DE
    Gynecol Oncol; 2010 Dec; 119(3):564-70. PubMed ID: 20822802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model.
    Asadi-Ghalehni M; Rasaee MJ; RajabiBazl M; Khosravani M; Motaghinejad M; Javanmardi M; Khalili S; Modjtahedi H; Sadroddiny E
    Microbiol Immunol; 2017 Dec; 61(12):531-538. PubMed ID: 29023946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
    Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
    J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.
    Kaumaya PT
    Hum Vaccin Immunother; 2015; 11(6):1368-86. PubMed ID: 25874884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
    Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
    Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
    Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
    Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
    Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
    Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
    Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
    J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.
    Miller MJ; Foy KC; Overholser JP; Nahta R; Kaumaya PT
    Oncoimmunology; 2014 Nov; 3(11):e956012. PubMed ID: 25941588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.
    Foy KC; Miller MJ; Overholser J; Donnelly SM; Nahta R; Kaumaya PT
    Oncoimmunology; 2014 Nov; 3(11):e956005. PubMed ID: 25941587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoprotective effect of an in silico designed multiepitope cancer vaccine with BORIS cancer-testis antigen target in a murine mammary carcinoma model.
    Mahdevar E; Kefayat A; Safavi A; Behnia A; Hejazi SH; Javid A; Ghahremani F
    Sci Rep; 2021 Nov; 11(1):23121. PubMed ID: 34848739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.